This product is a second-generation sulfonylurea antidiabetic drug that can reduce fasting and postprandial blood sugar and reduce glycosylated hemoglobin (HbAlc) by 1% to 2%. The main function of this type of drug is to stimulate pancreatic b cells to secrete insulin, but the prerequisite is that pancreatic b cells still have a certain function of synthesizing and secreting insulin. Its mechanism is to specifically bind to the sulfonylurea receptor on the b cell membrane, thereby closing the K channel, causing changes in membrane potential, opening the Ca2 channel, and increasing intracellular Ca2, which promotes insulin secretion. In addition, there are extra-pancreatic effects, including improving the insulin resistance of peripheral tissues (such as liver, muscle, and fat).

It can form a thin film on the surface of damaged gastric mucosa, thereby resisting the invasion of gastric acid on the mucosa and protecting the gastric mucosa. In addition, sucralfate can absorb pepsin and neutralize gastric acid, but the effect is weak.